1 |
Guidance and Practice in the Diagnosis and Management of Two Rare Inherited Metabolic DiseasesKazakova, Alessia 04 September 2018 (has links)
By facilitating timely diagnosis and treatment initiation, population-wide newborn screening programs have led to important reductions in morbidity and mortality for many rare diseases, including medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. Newborn screening has also expanded the spectrum of disease severity for MCAD and VLCAD deficiencies to include a higher proportion of milder cases, raising questions about appropriate disease management. To date there has been no systematic attempt to characterize best management practices in terms of the guidance that is available to those who provide care for MCAD and VCLAD deficiencies; nor has there been an attempt to understand the extent to which current practices align with such currently available guidance. The two projects that are part of this thesis sought to address these research gaps with a particular focus on two key disease-specific management practices we identified in advance as priorities: the use of carnitine supplementation and the recommended duration of fasting.
The objective of the first project was to systematically review the quality and content of clinical practice guidelines and/or recommendations for the diagnosis and management of both MCAD and VLCAD deficiencies. Two independent reviewers assessed the eligibility of citations retrieved from a comprehensive search of the peer-reviewed and grey literature. We appraised the quality of the reviewed guidance and extracted information on the content of recommendations. From the 25 guidance documents that met our inclusion criteria, only 7 incorporated evidence reviews, indicating that guidance in this field does not generally meet established methodological standards for the rigorous development of clinical practice guidelines. With respect to content, we identified unclear and inconsistent recommendations regarding fasting times and the use of carnitine supplementation. Further empirical evidence in these areas is necessary to inform the development of future rigorous guidelines.
The objective of the second project was to identify actual practices in the management of MCAD deficiency. We conducted a scoping review of published literature on treatment practices around the world and a secondary analysis of data documenting treatments received by participants in a Canadian pediatric cohort study. For the scoping review, citations retrieved from our comprehensive search strategy were screened by two independent reviewers. We extracted information on study characteristics and disease management. Our secondary analysis included longitudinal data for Canadian children with MCAD deficiency, born between 2006 and 2015 and enrolled in a cohort study at one of 13 centres. For both project components, we described carnitine supplementation and fasting times, overall and according to potential indicators of disease severity (genotype, biochemical phenotype). We identified 5 relevant publications in the scoping review and analyzed data for 107 children participating in the Canadian cohort. Management practices related to carnitine supplementation and fasting times for MCAD deficiency were highly variable based on both data sources. There was some evidence of an association between genotype and carnitine use, which, based on the scoping review, may be due to a relationship between genotype and carnitine deficiency. While actual practice was in some ways aligned with the guidance we reviewed in the first project, these results underscore the need for further evidence to address areas of uncertainty that have been prioritized by patients and families, clinicians, and health researchers, including questions regarding the potential to tailor treatment to predicted disease severity and an emphasis on controversial therapies such as carnitine supplementation.
|
2 |
Experiences of Parents of Children Diagnosed with Inherited Metabolic Diseases (IMD) in Canada: Qualitative Description and Identification of Patient- and Family-Centred OutcomesSiddiq, Shabnaz January 2016 (has links)
Objectives: The objectives of this thesis were to: (i) understand the experiences of parents/caregivers of children with inherited metabolic diseases (IMDs), including perceptions of the health care system; and (ii) identify important patient/family-centred outcomes for measurement in future studies.
Methods: A qualitative study used semi-structured interviews to gain in-depth insight into caregivers’ experiences. In an adapted meta-synthesis study, the qualitative findings were integrated with the results of related research to identify priority outcomes.
Results: Twenty-one caregivers were interviewed. Participants described adjusting to the management of their child’s illness through specific coping strategies but reported stress related to social development. While generally satisfied with disease-specific care, participants described negative experiences with non IMD-specific health services. Health-related quality of life, parental coping, and specific experiences with health care emerged as high-priority outcomes.
Conclusions: This project contributes to the limited published literature on caregiver experiences with pediatric IMD and informs future patient-centred research.
|
3 |
Parent Perceptions of Health Care Networks for Children with Inherited Metabolic Diseases: A Mixed Methods StudyAl-Baldawi, Zobaida 29 June 2022 (has links)
Objectives: The aim of this study was to gain a thorough understanding of parents’ perceptions of and experiences with the care networks surrounding young children (<=12 years) with inherited metabolic diseases (IMDs).
Methods: In this mixed methods study, parent participants created a ‘care map’ depicting their child’s network of care providers. We analyzed care maps using social network analysis. A subset of parents participated in a semi-structured interview. We analyzed interviews thematically and integrated quantitative and qualitative results narratively.
Results: Sixty parents contributed care maps and 10 participated in interviews. Parent-drawn care networks were large with few connections between providers. Parents felt responsible for creating and maintaining care networks and for coordinating care. They valued providers who trusted them as part of their child’s health care team.
Conclusions: Our findings highlight the complexity of care for children with IMDs and can inform the design of interventions to improve care.
|
4 |
Využití HPLC a LC-MS/MS metod v diagnostice dědičných metabolických poruch / HPLC and LC-MS/MS methods for diagnosis of inherited metabolic diseasesBártl, Josef January 2014 (has links)
This dissertation thesis is focused on development and optimization of high- performance liquid chromatography (HPLC) and tandem mass spectrometry (LC-MS/MS) methods, and its utility for diagnosis of inherited metabolic diseases. The first thematic part describes a comprehensive laboratory approach to diagnostics of patients with hereditary xanthinuria by determination of specific markers and enzyme activity. For this purpose HPLC method with diode array detection for measurement of hypoxanthine, xanthine, allopurinol and oxypurinol in urine and plasma and HPLC method with fluorimetric detection for analysis of pterin and isoxanthopterin in plasma were employed. These methods were successfully applied in clinical practice to ascertain two patients with hereditary xanthinuria type I. The second thematic part aims at developing and clinical application of new LC-MS/MS method for simultaneous determination of total homocysteine (tHcy), methionine (Met) and cystathionine (Cysta) in dried blood spots (DBS) and plasma. The results demonstrated the clinical utility of this method for detection of patients with homocystinuria and possibility to distinguish between defects in the remethylation and transsulfuration pathways of homocysteine metabolism. Due to ease of DBS collection and sample transportation...
|
5 |
Métabolisme de l'acétyl-CoA : modulation pharmacologique, approches thérapeutiques et nouvelles maladies / Acetyl-coA metabolism : pharmacological treatment, therapeutic approaches and new diseasesHabarou, Florence 24 November 2016 (has links)
L’acétyl-coA occupe une place centrale dans le métabolisme intermédiaire. Il constitue le point de jonction de plusieurs voies métaboliques telles que la .-oxydation, la glycolyse, le catabolisme de certains acides aminés, la cétolyse, la cétogenèse et la synthèse d’acides gras. Il est également impliqué dans d’autres processus tels que l’acétylation des protéines. Au cours de mon travail de thèse, je me suis attachée à étudier différents aspects du métabolisme de l’acétyl-coA. La première partie de mon travail a porté sur la modulation pharmacologique de la .- oxydation dans le but de corriger des déficits de cette voie métabolique. L’intérêt de traitements par 400µM de bézafibrate ou 75µM de resvératrol dans les formes modérées de déficit en VLCAD et en CPT2 avait été montré précédemment. Par des méthodes de référence et grâce à la mise au point de nouvelles techniques, j’ai pu montrer sur des fibroblastes de patients déficitaires en LCHAD que des traitements par une combinaison de 35µM de bézafibrate et 30µM de resvératrol permettent d’augmenter les capacités d’oxydation du palmitate en stimulant la synthèse protéique. L’effet de cette combinaison était comparable à celui d’un traitement par 400µM de bézafibrate. Dans un second temps, je me suis intéressée à deux cofacteurs impliqués dans le métabolisme de l’acétyl-coA : l’acide lipoïque, cofacteur de quatre .-cétoacides déshydrogénases (PDHc, BCKDHc, .- KGDHc et GCS) et la riboflavine, cofacteur d’acyl-coA déshydrogénases de la .-oxydation et de déshydrogénases impliquées dans le catabolisme des acides aminés ramifiés. Ainsi, j’ai participé à la description d’anomalies du métabolisme de l’acide lipoïque, un nouveau groupe de maladies héréditaires du métabolisme caractérisé par un déficit combiné en .-cétoacides déshydrogénases. Par ailleurs, j’ai pu montrer qu’une hyperprolinémie constitue un biomarqueur intéressant pour le diagnostic d’acidurie glutarique de type II primaire ou secondaire, ces dernières pouvant se rencontrer en cas d’anomalie du métabolisme de la riboflavine. J’ai également évalué l’utilisation d’un mélange racémique de L,D-3-hydroxybutyrate afin de corriger les déficits énergétiques induits par un déficit en PDHc ou GLUT1. Via la cétolyse, le L,D-3- hydroxybutyrate génère de l’acétyl-coA. De façon surprenante, l’administration de ce composé s’est traduite par une amélioration de l’état clinique des patients atteints de déficits en PDHc, alors qu’une dégradation a été observée chez les patients atteints de déficits en GLUT1. Cette évolution différente pourrait souligner l’importance de l’anaplérose chez les patients déficitaires en GLUT1. Enfin, la dernière partie de mon travail de thèse porte sur la description d’un patient atteint d’une forme modérée de déficit en pyruvate carboxylase, cette enzyme étant régulée par l’acétyl-coA. Les difficultés diagnostiques rencontrées devant ces formes modérées sont rapportées, ainsi que des essais de traitement par des composés anaplérotiques et par le bézafibrate, malheureusement sans bénéfice net que ce soit in vitro ou in vivo. En conclusion, le métabolisme de l’acétyl-coA est altéré dans de nombreuses maladies héréditaires du métabolisme, dont certaines sont de description récente. Il peut être modulé par différentes approches pharmacologiques. Le développement de nouvelles techniques et notamment les analyses de flux métaboliques fournissent des outils utiles à son exploration et à l’étude de nouveaux traitements. / Acetyl-CoA is crucial for intermediary metabolism. It is at the crossroad of several metabolic pathways such as beta-oxidation, glycolysis, aminoacid catabolism, ketolysis, and fatty acid synthesis. It is also involved in other processes such as protein acetylation. In this document I studied different aspects of acetyl-CoA metabolism. First, I tried to correct fatty acid oxidation defects through pharmacological approach. Thanks to well- known methods and new ones, I showed that a combination of 30µM resveratrol and 35µM bezafibrate increased fatty acid oxidation capacities by increasing protein synthesis, as well as 400µM bezafibrate. Acetyl-CoA metabolism is also altered due to cofactors defects such as lipoic acid or riboflavine deficiency. I was involved in new diseases description and research for new biomarkers in this context. PDHc and GLUT1 deficiency are two different diseases with the same consequence : a defect in acetyl- CoA production from glucose. In order to improve patients’ quality of life, I evaluated the substitution of ketogenic diet with a racemic mix of L,D-3-hydroxybutyrate in PDHc and GLUT1 deficiency. The clinical evolution of patients was strikingly different, with an improvement in PDHc patients, whereas a degradation was noticed in GLUT1 patients. This difference might underline the role of anaplerosis in GLUT1 deficiency. Finally, I evaluated anaplerotic treatment and bezafibrate treatment in pyruvate carboxylase deficiency, an enzyme allosterically regulated by acetyl-CoA. To conclude, acetyl-CoA metabolism is altered in numerous inherited errors of metabolism, some of them being recently described. It can be modulated by pharmacological approaches. The development of new techniques such as metabolic flux analysis are useful for its study and for new treatments evaluation.
|
Page generated in 0.0864 seconds